Next Article in Journal
stim2b Knockout Induces Hyperactivity and Susceptibility to Seizures in Zebrafish Larvae
Next Article in Special Issue
Regulation of Apoptosis by the Bcl-2 Family of Proteins: Field on a Brink
Previous Article in Journal
In Vitro-Generated Hypertrophic-Like Adipocytes Displaying PPARG Isoforms Unbalance Recapitulate Adipocyte Dysfunctions In Vivo
Previous Article in Special Issue
Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
Review

Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer

Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy
*
Author to whom correspondence should be addressed.
Cells 2020, 9(5), 1287; https://doi.org/10.3390/cells9051287
Received: 28 April 2020 / Revised: 18 May 2020 / Accepted: 19 May 2020 / Published: 21 May 2020
(This article belongs to the Special Issue Regulation of Apoptosis by the Bcl-2 Family of Proteins)
The dynamic interplay between pro-death and pro-survival Bcl-2 family proteins is responsible for a cell’s fate. Due to the recognized relevance of this family in cancer progression and response to therapy, different efforts have made in recent years in order to develop small molecules able to target anti-apoptotic proteins such as Bcl-2, Bcl-xL and Mcl-1. The limitations of the first Bcl-2 family targeted drugs, regarding on-target and off-target toxicities, have been overcome with the development of venetoclax (ABT-199), the first BH3 mimetic inhibitor approved by the FDA. The purpose of this review is to discuss the state-of-the-art in the development of drugs targeting Bcl-2 anti-apoptotic proteins and to highlight the potential of their application as single agents or in combination for improving anti-cancer therapy, focusing in particular on solid tumors. View Full-Text
Keywords: cancer; Bcl-2; inhibitors cancer; Bcl-2; inhibitors
Show Figures

Graphical abstract

MDPI and ACS Style

D’Aguanno, S.; Del Bufalo, D. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells 2020, 9, 1287. https://doi.org/10.3390/cells9051287

AMA Style

D’Aguanno S, Del Bufalo D. Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells. 2020; 9(5):1287. https://doi.org/10.3390/cells9051287

Chicago/Turabian Style

D’Aguanno, Simona, and Donatella Del Bufalo. 2020. "Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer" Cells 9, no. 5: 1287. https://doi.org/10.3390/cells9051287

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop